Nuveen LLC Acquires Shares of 16,186 CeriBell, Inc. $CBLL

Nuveen LLC acquired a new stake in CeriBell, Inc. (NASDAQ:CBLL) in the first quarter, Holdings Channel reports. The institutional investor acquired 16,186 shares of the company’s stock, valued at approximately $311,000.

A number of other institutional investors and hedge funds have also modified their holdings of CBLL. KLP Kapitalforvaltning AS purchased a new stake in shares of CeriBell during the first quarter worth about $36,000. Tower Research Capital LLC TRC purchased a new stake in shares of CeriBell during the fourth quarter worth about $37,000. BNP Paribas Financial Markets purchased a new stake in shares of CeriBell during the fourth quarter worth about $43,000. New York State Common Retirement Fund purchased a new stake in shares of CeriBell during the first quarter worth about $67,000. Finally, Wells Fargo & Company MN purchased a new stake in shares of CeriBell during the fourth quarter worth about $167,000.

Insider Activity

In other CeriBell news, Director Rebecca B. Robertson sold 20,000 shares of the business’s stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $17.14, for a total value of $342,800.00. Following the transaction, the director directly owned 28,675 shares in the company, valued at $491,489.50. The trade was a 41.09% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Xingjuan Chao sold 25,000 shares of the business’s stock in a transaction dated Monday, July 7th. The shares were sold at an average price of $17.70, for a total transaction of $442,500.00. Following the completion of the transaction, the chief executive officer owned 776,022 shares in the company, valued at $13,735,589.40. The trade was a 3.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 64,499 shares of company stock worth $1,126,402 over the last quarter. 20.10% of the stock is currently owned by company insiders.

CeriBell Stock Down 4.3%

Shares of NASDAQ CBLL opened at $11.80 on Friday. CeriBell, Inc. has a 12-month low of $10.01 and a 12-month high of $32.75. The stock has a market cap of $432.59 million and a PE ratio of -3.95. The company has a current ratio of 13.31, a quick ratio of 12.91 and a debt-to-equity ratio of 0.11. The company has a 50-day moving average of $14.24 and a 200 day moving average of $17.06.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.02. The company had revenue of $21.20 million during the quarter, compared to analysts’ expectations of $20.52 million. CeriBell had a negative net margin of 63.83% and a negative return on equity of 48.42%. CeriBell has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, BTIG Research began coverage on CeriBell in a research note on Tuesday, June 24th. They issued a “buy” rating and a $30.00 price target on the stock. Eight investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $32.14.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.